EligibleTrials

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Recruiting · NCT06944522 · Interventional (participants receive a specific treatment) · Lead sponsor: BlueRock Therapeutics

View the official record on ClinicalTrials.gov →
Parkinson's disease

Interventions studied

Sham surgerybemdaneprocel

What this trial is about

Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

Who can take part

Age range
45 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

43 locations listed across 23 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.